ATXS Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Astria Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.55 |
| 52 Week High | US$16.90 |
| 52 Week Low | US$5.88 |
| Beta | 0.67 |
| 1 Month Change | 1.92% |
| 3 Month Change | -17.74% |
| 1 Year Change | 54.78% |
| 3 Year Change | 64.09% |
| 5 Year Change | -73.52% |
| Change since IPO | -98.78% |
Recent News & Updates
Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema
Nov 27Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth
Nov 14
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely
Jul 11Recent updates
Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema
Nov 27Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth
Nov 14We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely
Jul 11Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field
Jun 24Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout
Feb 04We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth
Dec 10We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth
Jul 27We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate
Apr 03Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation
Nov 30We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely
Aug 01Dr. Chris Morabito is the new medical chief of Astria Therapeutics
Jul 15Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition
Jun 30Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital
Jun 15Catabasis Pharma shares surge after Quellis Biosciences deal
Jan 29Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?
Dec 10
Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma
Oct 29Shareholder Returns
| ATXS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.0% | -2.5% | 0.1% |
| 1Y | 54.8% | 3.1% | 26.1% |
Return vs Industry: ATXS exceeded the US Biotechs industry which returned 3.7% over the past year.
Return vs Market: ATXS exceeded the US Market which returned 27.3% over the past year.
Price Volatility
| ATXS volatility | |
|---|---|
| ATXS Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ATXS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ATXS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 59 | Jill Milne | www.astriatx.com |
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching.
Astria Therapeutics, Inc. Fundamentals Summary
| ATXS fundamental statistics | |
|---|---|
| Market cap | US$545.72m |
| Earnings (TTM) | -US$100.04m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.4x
P/E RatioIs ATXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATXS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$100.04m |
| Earnings | -US$100.04m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.77 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ATXS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/17 23:39 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Astria Therapeutics, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Liisa Bayko | Evercore ISI |
| Joseph Pantginis | H.C. Wainwright & Co. |
| Carol Werther | H.C. Wainwright & Co. |